908 Devices to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
908 Devices Inc. (Nasdaq: MASS) announced it will release its financial results for the fourth quarter and full year 2025 before the market opens on Tuesday, March 3, 2026. Management will host a webcast conference call at 8:30 a.m. Eastern Time, accessible via the "Investors" section of their website. The company specializes in handheld chemical analysis tools for health, safety, and defense applications.
908 Devices accelerates chemical identification with MX908 for safer handling
908 Devices has launched its new MX908 device, designed to improve chemical identification for faster and more secure decision-making. This product provides clear chemical analysis, which is crucial for investigations and legal prosecutions. The company highlights the MX908's reliability in results, aligning with its commitment to advanced corrections technology and trace detection for enhanced facility safety.
908 Devices Reports Strong Growth and Technological Advancements
908 Devices delivered a strong financial performance in 2025, with revenue reaching $56.0 million, exceeding projections. The company also rolled out significant software upgrades for its MX908 mass spectrometer, enhancing its chemical analysis capabilities for first responders. The market for portable mass spectrometry is expected to grow significantly, with 908 Devices well-positioned to capitalize on this trend.
908 Devices Enhances MX908 Usability and Adds New Drug Targets
908 Devices Inc. has released new enhancements for its MX908 mass spectrometry device, improving usability and expanding its drug detection capabilities. The updates include a new TIC (toxic industrial chemical) Hunter mission mode for hazardous vapor sampling and the addition of five priority drug targets, such as medetomidine ("rhino tranq"), N-isopropyl butylone, ADB-PINACA, MDMB-BINACA, and Bromazolam. These enhancements aim to provide first responders with faster and more reliable chemical identification for critical decision-making in evolving threat landscapes.
Griffith, 908 Devices CFO, sells $143k in MASS stock By Investing.com
Joseph H. Griffith IV, CFO of 908 Devices Inc. (NASDAQ:MASS), sold 23,175 shares for approximately $143,221 on February 2, 2026. This transaction occurred shortly after he acquired 70,035 shares through Restricted Stock Units on February 1, 2026, and despite the stock showing a significant 171.73% return over the past year. InvestingPro analysis suggests the stock is undervalued, and the company maintains a strong financial position with more cash than debt.
908 Devices (NASDAQ:MASS) CFO Sells $143,221.50 in Stock
908 Devices Inc. (NASDAQ:MASS) CFO Joseph Iv Griffith sold 23,175 shares of the company's stock for a total of $143,221.50, reducing his position by 14.21%. The shares traded up 4% to $6.44, with the company having a market cap of $233.06 million and a negative P/E ratio. The company missed recent quarterly EPS expectations, and analysts currently have a "Hold" rating with an average price target of $12.00, while Weiss Ratings reiterated a "sell" rating.
Griffith, 908 Devices CFO, sells $143k in MASS stock
Joseph H. Griffith IV, CFO of 908 Devices Inc. (NASDAQ:MASS), sold 23,175 shares worth approximately $143,221 on February 2, 2026, after the stock experienced a significant annual return. Despite this sale, Griffith also acquired over 70,000 shares through Restricted Stock Units and Stock Options, and the company reported strong preliminary revenue for 2025 while maintaining a healthy financial position. InvestingPro analysis suggests the stock may be undervalued, offering further insights for investors.
Griffith, 908 Devices CFO, sells $143k in MASS stock
Joseph H. Griffith IV, CFO of 908 Devices Inc. (NASDAQ:MASS), sold 23,175 shares for approximately $143,221 on February 2, 2026, with the stock trading near $6.44 and having returned 171.73% over the past year. He also acquired 70,035 shares through restricted stock units and further stock options and RSUs on February 1, 2026. The company shows strong momentum with a 22.67% year-to-date gain, holds more cash than debt, and reported preliminary unaudited revenue of $56 million for 2025.
908 Devices Inc.'s (NASDAQ:MASS) 29% Price Boost Is Out Of Tune With Revenues
908 Devices Inc. (NASDAQ:MASS) recently saw its share price rebound by 29% in 30 days, contributing to a 152% annual gain. Despite this surge, its high price-to-sales (P/S) ratio of 3.9x is concerning given that the company's revenue is forecast to decrease by 3.5% next year, while the broader Electronic industry is expected to grow by 20%. Investors are cautioned that the elevated P/S ratio and anticipated revenue decline suggest the current stock prices may not be sustainable.
908 Devices Inc.'s (NASDAQ:MASS) 29% Price Boost Is Out Of Tune With Revenues
908 Devices Inc. (NASDAQ:MASS) recently experienced a 29% stock price rebound, contributing to a 152% annual gain. However, the company's Price-to-Sales (P/S) ratio of 3.9x is considered high compared to the industry average of 2.8x. Analysts project a 3.5% revenue decrease for the coming year, while the broader electronic industry is expected to grow by 20%, raising concerns about the sustainability of the current stock valuation despite past revenue growth.
908 Devices Q4 sales jump 20% as it turns Adjusted EBITDA positive
908 Devices Inc. announced strong preliminary unaudited financial results for Q4 and full year 2025, with Q4 revenue increasing by 20% to $17.2 million and full year revenue reaching approximately $56.0 million, a 17% growth. The company achieved its goal of positive Adjusted EBITDA in the fourth quarter. This performance was attributed to robust sales in U.S. state and local channels, international adoption of VipIR, and sales to federal and defense customers, positioning the company for future growth.
908 Devices reports preliminary Q4 revenue $17.2M, consensus $15.92M
908 Devices reported preliminary Q4 revenue of $17.2M, surpassing the consensus estimate of $15.92M. This strong performance was attributed to growth in the U.S. state and local channels, international adoption of VipIR, and sales to federal and defense customers. CEO Kevin Knopp highlighted the company's transformation to a "stronger, simpler, and more profitable financial model" focusing on frontline chemical detection, achieving positive Adjusted EBITDA in Q4, and benefiting from macro trends like increased funding for the fentanyl crisis and global defense budgets.
908 Devices Announces Strong Preliminary Financial Results for Fourth Quarter and Full Year 2025
908 Devices Inc. (Nasdaq: MASS) announced strong preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. The company expects full-year 2025 revenue of approximately $56 million, representing a 17% year-over-year growth, and achieved its goal of positive Adjusted EBITDA in the fourth quarter. This performance was attributed to strong U.S. state and local channel sales, international VipIR adoption, and sales to federal and defense customers, positioning the company for future growth.
908 Devices Launches a 3-in-1 Handheld Analyzer
908 Devices has launched VipIR, a 3-in-1 handheld analyzer designed for rapid and reliable field-based chemical identification of unknown bulk solids and liquids, including hazardous compounds, explosives, and drugs. Utilizing patented Smart Spectral Processing (SSP), VipIR dynamically combines data from FTIR and Raman spectroscopy from a single sample to provide accurate chemical identification. This device aims to streamline processes and remove uncertainty for hazardous response teams and border staff.
Investors push 908 Devices (NASDAQ:MASS) 12% lower this week, company's increasing losses might be to blame
908 Devices Inc. (NASDAQ:MASS) shares dropped 12% this week, though they are still up 185% over the last year. Despite the recent dip, the company has shown respectable revenue growth of 36% over the past year. However, 908 Devices is currently unprofitable, leading investors to question if the business is moving towards sustained profitability.
Investors push 908 Devices (NASDAQ:MASS) 12% lower this week, company's increasing losses might be to blame
Shares of 908 Devices Inc. (NASDAQ:MASS) experienced a 12% decline this week, despite an impressive 185% gain over the last year. The company, which is not yet profitable, saw its revenue grow by 36% in the past year, and insiders have made significant purchases, indicating potential confidence in its future trajectory. However, the recent drop and a five-year annualized loss of 14% suggest that investors should carefully consider the company's path to profitability and underlying fundamentals.
Investors push 908 Devices (NASDAQ:MASS) 12% lower this week, company's increasing losses might be to blame
908 Devices (NASDAQ:MASS) shares dropped 12% this week, despite an impressive 185% gain over the last year. The company is not yet profitable, but its revenue grew by 36% in the past year, indicating some progress. Investors are encouraged to research fundamentals and analyst forecasts rather than being swayed by the "fear of missing out."
GM Advisory Group LLC Takes $8.31 Million Position in 908 Devices Inc. $MASS
GM Advisory Group LLC recently acquired a significant position of 1,165,291 shares, valued at $8.31 million, in 908 Devices Inc. during the second quarter, representing 3.25% of the company. Institutional investors now own 88.06% of the company, while insiders hold 23.70%, despite some recent insider selling. Analysts have a "Moderate Buy" consensus rating with an average target price of $9.00, following a quarter where the company beat revenue estimates but missed EPS expectations.
908 Devices (NASDAQ: MASS) supplies 23 MX908s to U.S. Coast Guard, fleet now 35+
908 Devices Inc. announced that the U.S. Coast Guard has purchased 23 additional MX908 devices for chemical threat identification, bringing their total fleet to over 35 units. These handheld mass spectrometers are used for narcotics interdiction and hazardous threat detection, enabling rapid and accurate detection of substances like drugs, explosives, and other hazardous materials. The devices assist highly trained units in safeguarding ports, waterways, and coastal communities.
Some 908 Devices Inc. (NASDAQ:MASS) Shareholders Look For Exit As Shares Take 26% Pounding
908 Devices Inc. (NASDAQ:MASS) shares recently dropped 26%, despite a strong 102% gain over the last year. The company's high price-to-sales (P/S) ratio of 3.3x is concerning, especially as analysts forecast a 2.6% revenue decline for the coming year, while the broader industry is expected to grow by 15%. This suggests investors might be overvaluing the stock given the negative growth outlook.
908 Devices to Participate in Upcoming Investor Conferences
908 Devices Inc. (Nasdaq: MASS) announced its participation in the Stifel Healthcare Conference on November 12 and the 27th Annual Stephens Investment Conference on November 20. The company will host fireside chats at both events, with webcasts available on its investor relations website. These participations highlight 908 Devices' engagement with the investor community, showcasing its handheld chemical analysis tools for health, safety, and defense applications.
Earnings call transcript: 908 Devices reports Q3 2025 revenue growth amid EPS miss
908 Devices Inc. reported mixed Q3 2025 earnings, with revenue exceeding forecasts at $14 million but EPS missing significantly at a loss of $0.41, leading to a 19.51% pre-market stock decline. Despite the EPS miss, the company maintains its full-year revenue guidance of $54 million to $56 million and aims for adjusted EBITDA positivity in Q4 2025, driven by strategic advancements like the Explorer and VIPER devices and cost-saving initiatives. The company acknowledges potential Q4 revenue impacts from government shutdowns but views these as timing issues, expecting continued growth in 2026.
908 Devices Loses US$55m Market Value But Insiders See Windfall Of US$82k
Insiders at 908 Devices Inc. who bought shares in the past year have seen their investment grow by US$82k, despite a recent 19% stock price decline. This suggests insiders still see value in the company, especially given that a large purchase was made below the current stock price. Insider ownership stands at 8.4%, indicating some alignment between management and shareholders.
908 Devices Reports Third Quarter 2025 Financial Results and Reiterates 2025 Revenue Outlook
908 Devices Inc. (Nasdaq: MASS) reported its third-quarter 2025 financial results, with year-to-date revenue increasing 16% and adjusted EBITDA loss improving by 53% quarter over quarter. The company reiterated its full-year 2025 revenue outlook of $54.0 million to $56.0 million, representing 13% to 17% growth. These results highlight structural improvements in their cost base and strong demand, particularly for FTIR products.
908 Devices Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results
908 Devices Inc. announced preliminary unaudited financial results for Q4 and full year 2024, expecting approximately $17.2 million in revenue for Q4 and $58.0 million for the full year, representing growth of 20% and 15% respectively. The company met its revenue guidance and saw strong performance in both handheld and desktop segments, including significant contributions from the RedWave Technology acquisition. Cash, cash equivalents, and marketable securities were approximately $69.5 million at the quarter's end.
908 Devices Announces Preliminary First Quarter 2025 Financial Results
908 Devices Inc. announced preliminary unaudited financial results for the first quarter of 2025, anticipating at least $11.5 million in revenue from continuing operations, representing approximately 55% growth year-over-year. The company reported approximately $124 million in cash, cash equivalents, and marketable securities, with an additional $4.0 million in escrow from the recent divestiture of its desktop portfolio. This divestiture allows the company to focus on its advanced chemical detection strategy, aiming for Adjusted EBITDA positivity by Q4 2025.
United States Marine Corps purchases 908 Devices’ XplorIR gas identification devices - FireRescue1
The United States Marine Corps has purchased 908 Devices’ XplorIR gas identification devices for deployment at installations both within the U.S. and overseas. These devices will support the CBRNE-IPP program, aimed at protecting Marine Corps personnel and facilities from chemical, biological, radiation, nuclear, and explosive threats, as well as hazardous materials incidents. The XplorIR, a handheld device, can rapidly detect, identify, and quantify over 5,000 unknown gas and vapor chemical threats, enhancing real-time response capabilities.
908 Devices (MASS) Secures Major Order from U.S. Marine Corps - GuruFocus
908 Devices Inc. (MASS) has secured a significant contract with the U.S. Marine Corps for 17 XplorIR devices, designed for hazardous gas and vapor detection. Despite this major order, the company faces challenges in profitability with negative operating and net margins. However, it maintains a strong liquidity position and low debt, alongside substantial institutional ownership.
17 XplorIR Units: 908 Devices Supplies U.S. Marine Corps with Handheld Gas ID for Deployment - Stock Titan
908 Devices announced that the U.S. Marine Corps CBRNE Installation and Protection Program purchased 17 XplorIR units for handheld gas identification. These devices will be deployed at installations both within the United States and overseas to protect against CBRNE and hazardous materials incidents. The XplorIR device rapidly detects, identifies, and quantifies over 5,000 unknown gas and vapor chemical threats, complementing the Marine Corps' existing use of 908 Devices' MX908.
Analyzing ADM Tronics Unlimited (OTCMKTS:ADMT) & 908 Devices (NASDAQ:MASS)
This article compares ADM Tronics Unlimited (ADMT) and 908 Devices (MASS) across several financial metrics including risk, volatility, ownership, valuation, earnings, profitability, and analyst recommendations. It concludes that 908 Devices outperforms ADM Tronics Unlimited in most comparative factors. The article also provides company descriptions for both firms.
908 devices CFO Griffith sells $45k in shares
Joseph H. Griffith IV, CFO of 908 Devices Inc. (NASDAQ:MASS), sold 4,990 shares of company stock for a total of $45,246 in early October as the stock traded near its 52-week high. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan. The company recently reported strong Q2 2025 revenue of $13 million, surpassing forecasts, and received an upgrade from Leerink Partners to Outperform.
908 Devices Appoints Dr. Brandi Vann To Board
908 Devices Inc. (Nasdaq: MASS) has appointed Dr. Brandi Vann to its Board of Directors. Dr. Vann brings over 15 years of leadership experience at the U.S. Department of Defense, overseeing nuclear, chemical, and biological defense programs, which aligns with the company's strategic refocus on public health, safety, and defense tech. This appointment coincides with Jeff George stepping down from the board.
908 Devices to Report Second Quarter 2025 Financial Results on August 5, 2025
908 Devices Inc. (Nasdaq: MASS) announced it will release its second quarter 2025 financial results before market open on Tuesday, August 5, 2025. A corresponding conference call will be webcast starting at 8:30 a.m. Eastern Time, accessible via the "Investors" section of the company's website. The webcast will also be archived for replay.
908 Devices Launches VipIR, a 3-in-1 Handheld Analyzer for Field-Based Chemical Identification of Unknown Bulk Substances
908 Devices Inc. (Nasdaq: MASS) has launched VipIR, a 3-in-1 handheld analyzer designed for rapid and confident field-based chemical identification of unknown bulk solids and liquids, such as narcotics and explosives. Leveraging proprietary Smart Spectral Processing (SSP) that integrates Raman and FTIR spectroscopy, VipIR simplifies workflows for customs, border personnel, and hazardous response teams. This device provides accurate and reliable chemical identification, enhancing decision-making on-scene with features like an expansive chemical library and robust connectivity.
Christopher D. Brown Joins 908 Devices’ Board
Christopher D. Brown, co-founder of 908 Devices Inc., has been appointed to the company's board of directors. Brown previously served as the company's chief technology officer and vice president of Research & Development, and most recently as chief product officer until Repligen Corporation acquired 908 Devices’ bioprocessing portfolio. His extensive experience in advanced analytical technologies and innovation will be a valuable asset to the board.
908 Devices launches VipIR, a 3-in-1 handheld analyzer for field-based chemical identification of unknown bulk substances
908 Devices Inc. has launched VipIR, a 3-in-1 handheld analyzer designed for rapid and confident field-based chemical identification of unknown bulk solids and liquids such as narcotics, explosives, and toxic chemicals. The device utilizes Smart Spectral Processing (SSP) to integrate data from Raman and FTIR spectroscopy, providing accurate results from a single sample without repositioning or repeated sampling. VipIR aims to streamline workflows for customs, border personnel, and hazardous response teams, delivering reliable answers with its extensive chemical library and robust design.
When Every Second Counts: This UNC Device is Saving Lives
A device called the MX908, developed by UNC chemist J. Michael Ramsey and 908 Devices, Inc., is helping combat America's drug crisis by rapidly detecting illicit substances like fentanyl. This handheld mass spectrometer provides lab-grade results in under 60 seconds and is used globally by first responders and other personnel. With over 3,000 units deployed, this technology is praised for its life-saving impact.
908 Devices Reports First Quarter 2025 Financial Results and Reiterates 2025 Revenue Outlook
908 Devices reported strong first-quarter 2025 financial results, with revenue from continuing operations growing 59% year-over-year to $11.8 million, largely driven by an 86% increase in handheld product and service revenue. The company reiterated its full-year 2025 revenue guidance of $53 million to $55 million and remains committed to achieving adjusted EBITDA profitability by the fourth quarter. Recent highlights include the divestiture of its bioprocessing product portfolio and significant orders for its MX908 mass spectrometry devices for drug detection and hazardous materials testing.
908 Devices receives $2M order from the Texas Department of Public Safety for drug detection and mitigation
908 Devices Inc. has received a $2 million order from the Texas Department of Public Safety for its MX908 handheld mass spectrometry devices. These devices will be used for rapid drug detection and identification, particularly of synthetic opioids like fentanyl, to combat the opioid crisis across Texas. The order, funded by a COPS grant, expands on a previous purchase and will be deployed to critical interdiction locations.
908 Devices Announces Preliminary Q1 2025 Financial Results
908 Devices Inc. (MASS) has announced its preliminary financial results for the first quarter of 2025. The company expects Q1 2025 revenue from continuing operations to be at least $11.5 million, representing a 55% increase. This short report, sourced from Refinitiv, highlights the company's strong revenue growth projections.
Repligen lays down $70m to buy analytics tech from 908 Devices
Repligen has acquired upstream process analytical technology (PAT) assets from 908 Devices for $70 million, marking its entry into upstream PAT. The acquisition includes four bioprocessing PAT devices, facilities in North Carolina and Germany, and 81 staff members, complementing Repligen's existing downstream analytics portfolio. Jefferies analysts view this deal as a strategic move for Repligen, filling portfolio gaps and potentially opening doors for future M&A in the bioreactor and cell culture media space.
908 Devices Announces Strategic Transformation and Reports Fourth Quarter and Full Year 2024 Financial Results
908 Devices announced a strategic transformation, including the divestiture of its desktop portfolio to Repligen for $70 million, to sharpen its focus on high-growth handheld markets and public health and safety solutions. The company reported a 31% increase in Q4 2024 revenue and a 19% increase for the full year 2024, expecting to achieve Adjusted EBITDA positivity by Q4 2025 and cash flow positivity in 2026. This repositioning aims to accelerate top-line growth, pulling forward profitability through improved gross margins and reduced operating expenses.
908 Devices Inc. erwartet einen Verlust von 35 Cents pro Aktie - Earnings Preview
908 Devices Inc. (MASS) wird voraussichtlich am 3. März seine Quartalsergebnisse für den Zeitraum bis zum 31. Dezember 2024 veröffentlichen. Analysten prognostizieren einen Umsatzanstieg von 14,2 Prozent auf 16,386 Mio. Dollar und einen Verlust von 35 Cents pro Aktie. Die durchschnittliche Analystenbewertung für die Aktie ist "Kaufen" bei einem Kursziel von 6,00 Dollar.
10 Biotech Companies in Germany to Know
This article highlights 10 prominent biotechnology companies in Germany, recognizing the sector's significant contribution to the country's economy and its role in health and life sciences. It details each company's focus, from drug development and research to medical devices and diagnostics, underscoring Germany's continuous investment in biotech innovation. The listed companies include Schrödinger, Eucalyptus, EMBL, Ottobock, Bio-Rad, Immatics, Evotec, 908 Devices, Boehringer Ingelheim, and Regeneron.
908 Devices Inc (MASS) Quarterly 10-Q Report
908 Devices Inc. (MASS) filed its 10-Q report for the quarter ending September 30, 2024, reporting increased revenue due to higher service revenue and the acquisition of RedWave Technology. Despite revenue growth, the company incurred a significant net loss of $29.3 million, largely due to a goodwill impairment charge. The company expects its current cash and revenue to fund operations for at least the next 12 months.
Simplifying Everyday Hazmat Calls with Advanced Technology
This article announces an upcoming webinar discussing how advanced technologies like Fourier Transform Infrared (FTIR) and High-Pressure Mass Spectrometry (HPMS) can simplify responses to everyday hazmat calls. Moderated by Dr. Mark Norman and featuring Phil Ambrose, the discussion will cover various hazmat scenarios, highlighting how these technologies can expedite responses and ensure safety for all involved, from first responders to the public. The webinar is sponsored by 908 Devices and aims to educate both engine companies and dedicated hazmat teams.
ProtectIR is Handheld Solid, Liquid Detection from 908 Devices
908 Devices introduces ProtectIR, a handheld FTIR technology for solid and liquid detection and analysis. This device is designed for hazardous materials, narcotics, and explosives identification in the field, utilizing a diamond attenuated total reflection (ATR) sample interface. It enables hazmat response teams, military, and first responders to analyze bulk substances quickly.
908 Devices enhances XplorIR portable analyzer to simultaneously identify and quantify hazardous gases and vapors
908 Devices Inc. has enhanced its XplorIR portable gas and vapor analyzer with a software update that allows it to identify and quantify nearly 5,000 airborne chemicals. This advancement provides first responders, HAZMAT teams, and fire departments with critical real-time information for managing hazardous material incidents. The XplorIR uses FTIR spectroscopy to simultaneously detect and quantify multiple compounds at the part-per-million level, continuously monitoring and updating chemical composition every four seconds.
908 Devices acquires RedWave Technology, expanding its forensics product offering
908 Devices Inc. has acquired RedWave Technology, a provider of portable FTIR spectroscopic analyzers, to expand its forensics product offering. This acquisition adds optical spectroscopy to 908 Devices' technology platform, providing an expanded portfolio of handheld chemical analysis devices for rapid chemical identification and bolstering its desktop portfolio. The acquisition involves an initial payment of $53.5 million and aims to accelerate strategic objectives by leveraging RedWave's innovative products and established sales channel.
MX908 Device Enables Correctional Facility Personnel to Quickly Identify Illegal Drugs in Incoming Mail
908 Devices Inc. announced that its MX908 handheld mass spec device is being utilized by correctional facilities, including the Minnesota Department of Corrections, to detect illegal drugs in incoming mail. The device helps protect correctional officers and inmates from drug exposure and prevent overdoses by quickly identifying trace amounts of illicit substances. This technology is already employed in prisons in Kentucky, Colorado, Indiana, and Minnesota, significantly enhancing safety and security by combating contraband introduction.
